Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Henagliflozin on Myocardial Fibrosis in Obese Patients (LY2026-317-C)

14 de novembro de 2026 atualizado por: Jing Ma

Effect of Henagliflozin on Myocardial Fibrosis in Obese Patients: A Prospective, Randomized, Controlled Study.

This study evaluates the anti-fibrotic efficacy and safety of henagliflozin versus metformin in non-diabetic obese patients with subclinical myocardial fibrosis, explores whether the benefit is mediated by metabolic improvement or direct myocardial protection, and aims to provide high-level evidence for early pharmacological intervention.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

This study will be based on an established specialized cohort of non-diabetic patients with simple obesity and a multi-omics database. By integrating clinical data with multidimensional information including genomics, metabolomics, and proteomics, patients at high risk of myocardial fibrosis will be identified. After myocardial fibrotic changes are further confirmed by CMR, eligible participants will be randomly assigned to the control group (metformin) or the intervention group (henagliflozin). The treatment period will be 24 weeks, followed by a 24-week safety follow-up period. The difference in the change in the degree of myocardial fibrosis before and after treatment between the two groups will be compared to determine the efficacy of henagliflozin in counteracting myocardial fibrosis in the non-diabetic obese population. This project aims to provide high-level evidence-based medical evidence for targeted pharmacological intervention of obesity-related early cardiac damage, with the goal of improving the long-term prognosis of this population.

Tipo de estudo

Intervencional

Inscrição (Estimado)

100

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. BMI ≥ 28 kg/m², or waist circumference ≥ 90 cm in men or ≥ 85 cm in women, or body fat percentage ≥ 25% in men or ≥ 30% in women;
  2. Adults aged 18 to 65 years;
  3. ECV greater than 30%;
  4. No participation in other clinical trials within the past three months.

Exclusion Criteria:

  1. Diagnosed with diabetes mellitus or prediabetes;
  2. History of coronary artery disease (coronary stenosis > 50% on coronary angiography or coronary computed tomography), history of myocardial infarction, history of coronary artery bypass grafting or percutaneous coronary intervention; non-ischemic cardiovascular diseases such as idiopathic cardiomyopathy, valvular disease, congenital heart disease, or cor pulmonale; arrhythmia or bundle branch block on electrocardiogram; implantation of a cardiac pacemaker or defibrillator;
  3. Uncontrolled hypertension: systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg during the screening visit (mean of three blood pressure measurements in the supine position);
  4. Symptomatic hypotension and/or systolic blood pressure < 90 mmHg at V1 or V2, or patients judged by the clinician to have hypovolemia;
  5. Use within 3 months of: 1) medications that may affect body weight or glucose metabolism, including systemic glucocorticoids (excluding topical, ophthalmic, nasal spray, or inhaled preparations; excluding low-dose or overnight dexamethasone suppression test use), growth hormone, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic/tetracyclic antipsychotic drugs, other psychiatric medications or sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts), etc.; 2) traditional Chinese medicines, Chinese patent medicines, herbal medicines, health supplements, meal replacements, etc., with weight-loss or glucose-lowering effects; 3) use of or current use of the following weight-loss drugs or drugs containing the following ingredients, such as: sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, clobenzorex, fenfluramine, amfepramone, lorcaserin, phentermine/topiramate combination, naltrexone/bupropion combination, etc.; 4) use of glucose-lowering drugs, such as metformin, α-glucosidase inhibitors, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, thiazolidinediones (TZDs), insulin, etc.;
  6. Other endocrine and metabolic diseases such as hyperthyroidism, hypothyroidism, acromegaly, diabetes insipidus, or Cushing's syndrome;
  7. Concurrent malignant tumors;
  8. Severe liver disease (Child-Pugh class C) or liver enzymes (ALT/AST) > 3 times the upper limit of normal;
  9. Estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73 m²;
  10. Cognitive impairment, or concomitant infectious or autoimmune diseases;
  11. History of recurrent urinary or reproductive tract infections;
  12. Patients who refuse henagliflozin or metformin treatment, or who are allergic to henagliflozin, metformin, or their excipients; those with incomplete questionnaires or incomplete data;
  13. Pregnant or breastfeeding women.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Grupo de Intervenção

Oral henagliflozin 10 mg once daily for 24 weeks, administered at a fixed dose without adjustment. Used in non-diabetic obese patients with subclinical myocardial fibrosis as an off-label investigational treatment.

Comparador Ativo: Control Group

oral metformin tablets 2000 mg/day; or the maximum tolerated dose (≥1000 mg/day).

Oral metformin titrated to 2000 mg/day (1000 mg twice daily), or the maximum tolerated dose (≥1000 mg/day), for 24 weeks. Dose titration: 500 mg twice daily for weeks 1-2, then 1000 mg twice daily from week 3 if tolerated.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Change from Baseline in Myocardial Extracellular Volume (ECV) Fraction at 24 Weeks
Prazo: Baseline to Week 24

Change from baseline in myocardial extracellular volume (ECV) fraction, as measured by cardiac magnetic resonance (CMR) T1 mapping pre- and post-contrast. ECV is calculated from pre- and post-contrast T1 relaxation times and the patient's hematocrit. The between-group difference in ΔECV (Henagliflozin vs. Metformin) will be compared; continuous data will be summarized as mean ± SD and analyzed using mixed-effects models.

Baseline to Week 24

Medidas de resultados secundários

Medida de resultado
Prazo
Change from Baseline in Epicardial Adipose Tissue (EAT) Volume at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Left Ventricular Ejection Fraction (LVEF) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Cardiac Output at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Heart Rate at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Peak Filling Rate at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Stroke Volume Index (BSA-corrected) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in End-Systolic Volume Index (BSA-corrected) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in End-Diastolic Volume Index (BSA-corrected) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Left Ventricular Mass Index (BSA-corrected) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Early-to-Late Filling Ratio (E/A) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in LV Mass to End-Diastolic Volume Ratio (MVR) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Cardiac Index at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Body Weight at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Body Mass Index (BMI) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Systolic Blood Pressure at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Diastolic Blood Pressure at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Glycated Hemoglobin (HbA1c) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Fasting Plasma Glucose at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in HOMA-IR (Insulin Resistance Index) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Total Cholesterol at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in High-Density Lipoprotein Cholesterol (HDL-C) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in Triglycerides at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24
Change from Baseline in High-sensitivity CRP (hsCRP) at 24 Weeks
Prazo: Baseline to Week 24
Baseline to Week 24

Outras medidas de resultado

Medida de resultado
Prazo
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Prazo: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Genitourinary Tract Infections
Prazo: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Gastrointestinal Adverse Events
Prazo: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Ketoacidosis
Prazo: Up to 48 Weeks
Up to 48 Weeks
Number of Participants With Serious Adverse Events (SAEs)
Prazo: Up to 48 Weeks
Up to 48 Weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Jing Ma, Department of Endocrinology, Shanghai Jiao Tong University School of Medicine Affiliated Renji Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de dezembro de 2026

Conclusão Primária (Estimado)

1 de outubro de 2028

Conclusão do estudo (Estimado)

1 de outubro de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

1 de novembro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

14 de novembro de 2026

Primeira postagem (Real)

19 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

19 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

14 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • LY2026-317-C

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .